Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An announcement from OncoSil Medical Ltd ( (AU:OSL) ) is now available.
OncoSil Medical Limited has appointed Ms. Lel Smits as a Non-Executive Director to its Board, leveraging her extensive expertise in governance, strategy, and corporate communications. Recognized for her achievements in finance and entrepreneurship, Ms. Smits is expected to enhance OncoSil’s strategic direction and support its mission to deliver innovative cancer treatments globally. This appointment is a strategic move to strengthen the company’s governance and investor relations, aligning with OncoSil’s commitment to improving patient outcomes and fostering growth.
More about OncoSil Medical Ltd
OncoSil Medical Limited (ASX:OSL) is a medical device company specializing in the development of cancer treatment devices, specifically the OncoSil™ brachytherapy device for the treatment of locally advanced unresectable pancreatic cancer. The device is designed to deliver targeted intratumoural placement of Phosphorous-32 in combination with chemotherapy. It has received breakthrough device designation in the European Union, United Kingdom, and the United States, and is approved for sale in over 30 countries.
Average Trading Volume: 9,407,035
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$23.03M
For an in-depth examination of OSL stock, go to TipRanks’ Stock Analysis page.
